Antimicrobial resistance

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

Retrieved on: 
Thursday, January 5, 2023
Innovation, Fungus, Cancer, Microsoft, Laniado Hospital, Antimicrobial resistance, Bacteria, Ministry, Therapy, Infection, Orphan, Virus, InterAction Council of Former Heads of State and Government, Ministry of Health (Saudi Arabia), BFM Business, CE, Letter, European Committee on Antimicrobial Susceptibility Testing, Parasitism, FDA, Hospital, BIOMED, Tel Aviv Stock Exchange, Prevalence, Survival, AST, Pharmaceutical industry, Antibiotics, Medical imaging, Medical device, Health, Bloodstream infections

Michael Poirier, Qualigen’s Chairman and CEO stated: “We are very encouraged by the milestones achieved and progress made to date by our partners in Israel.

Key Points: 
  • Michael Poirier, Qualigen’s Chairman and CEO stated: “We are very encouraged by the milestones achieved and progress made to date by our partners in Israel.
  • We believe NanoSynex’s AST may represent a breakthrough diagnostic test in the critical area of infectious disease.
  • Key accomplishments this year include:
    Closed majority investment transaction with our strategic partner Qualigen Therapeutics for enhanced product development and commercialization of our novel antimicrobial susceptibility test platform.
  • Completed development of our latest system design composed of disposable test cards, benchtop reader and real time data analysis software.

Recession Resister Launches Health Program To Fill Protection Gap For Families

Retrieved on: 
Saturday, November 26, 2022
Health, Telehealth, Spouse, Antimicrobial resistance, United States Public Health Service, Pharmacy, MRI, Prescription, CT, Health insurance

As the cost of medical treatment in the US continues to spiral, Recession Resister announces its latest healthcare coverage solutions for families through its partnership with LifeExec.

Key Points: 
  • The company offers members a full suite of pharmaceutical, dental, vision, telemedicine, and mental health services through its partner's flagship LifeExec Advantage Wellness membership.
  • The company augments the Advantage Wellness plans with expert planning guidance from the responsive customer service team.
  • The latest LifeExec Advantage Wellness plans offer a unique combination of no age restrictions, no restrictions on pre-existing conditions, and no limits on usage.
  • The program provides a fully transparent solution to meeting the cost of healthcare in the US today with no hidden fees.

Shionogi, Active Citizenship Network and MEPS Advocate for Urgent Policy Implementation in EU Member States at EU Parliament Event to Address the Growing Threat of Antimicrobial Resistance

Retrieved on: 
Monday, November 21, 2022
Biotechnology, Infectious Diseases, Hospitals, Health, Pharmaceutical, Benchmark, Member of the European Parliament, Marketing, AMR, European Commission, Central nervous system disease, Royal commission, Senior, World Health Organization, Council, WHO, Infection, HERA, Cleveland Clinic Journal of Medicine, Vulnerable, Gastroenterology, Environmental health, Lancet, Antimicrobial resistance, Medicine, Policy, CNS, European, Research, Bankruptcy, Degenerative disease, Transplant, Pain, Council Implementing Regulation (EU) No. 282/2011, Death, European Parliament, Health, Access, Patient, Pharmaceutical industry, Renewable energy, Risk management, EU, Shionogi

The event reinforced the need for urgent attention and collaboration from pharmaceutical companies, policy stakeholders and governments to bring about policy change and innovation to address this growing issue.

Key Points: 
  • The event reinforced the need for urgent attention and collaboration from pharmaceutical companies, policy stakeholders and governments to bring about policy change and innovation to address this growing issue.
  • The event also explored collaborative and governance models to achieve better implementation of actions and best practices for a holistic AMR approach.
  • The meeting was crucial to increase awareness of Antimicrobial Resistance and the need for new innovations to address unmet needs.
  • Apr 2013; 80(4): 22533
    4 Antimicrobial Resistance Benchmark 2021. https://accesstomedicinefoundation.org/media/uploads/downloads/61ee760d0... Last accessed November 2022
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221120005048/en/

New study reveals the extent of antibiotic misuse for a common sore throat, fuelling the 3rd leading cause of death worldwide

Retrieved on: 
Friday, November 18, 2022
Suffering, Sore throat, Anxiety, Common, Infection, GRIP, WAAW, Death, Workforce, STAR, Confusion, Education, Multimedia, Antimicrobial resistance, Sore, Upper respiratory tract infection, Virus, Pharmaceutical industry, Dietary supplement, Poultry, Trapping

Upper respiratory tract infections represent the leading cause for global antibiotic misuse in adults.

Key Points: 
  • Upper respiratory tract infections represent the leading cause for global antibiotic misuse in adults.
  • The STAR study findings suggest that a misunderstanding of how to treat sore throats is contributing to antibiotic overuse.
  • GRIP is calling for awareness and education on appropriate antibiotic use and urging young people to ask questions to help fight antibiotic resistance."
  • For more information or interviews with GRIP experts Sabiha Essack & Martin Duerden: [email protected] , +44 20 8154 6389
    View original content to download multimedia: https://www.prnewswire.com/news-releases/new-study-reveals-the-extent-of...

New study reveals the extent of antibiotic misuse for a common sore throat, fuelling the 3rd leading cause of death worldwide

Retrieved on: 
Friday, November 18, 2022
Suffering, Sore throat, Anxiety, Common, Infection, GRIP, WAAW, Death, Workforce, STAR, Confusion, Education, Antimicrobial resistance, Sore, Upper respiratory tract infection, Virus, Pharmaceutical industry, Dietary supplement, Poultry, Trapping

Upper respiratory tract infections represent the leading cause for global antibiotic misuse in adults.

Key Points: 
  • Upper respiratory tract infections represent the leading cause for global antibiotic misuse in adults.
  • The STAR study findings suggest that a misunderstanding of how to treat sore throats is contributing to antibiotic overuse.
  • GRIP is calling for awareness and education on appropriate antibiotic use and urging young people to ask questions to help fight antibiotic resistance."
  • For more information or interviews with GRIP experts Sabiha Essack & Martin Duerden: [email protected] , +44 20 8154 6389

Cepheid Launches Multiplex Vaginal Panel (MVP) to Support More Accurate Women's Health Diagnosis in U.S.

Retrieved on: 
Tuesday, November 15, 2022
MPH, DHR, Bacterial vaginosis, Recurrence, PCR, Yeast, Woman, Solution, Trichomoniasis, Obstetrics, Infection, Cepheid variable, Physician, Trichomonas, Antimicrobial resistance, Medical diagnosis, Role, Danaher Corporation, Gynaecology, Molecular biology, Genetic testing, Center, Cancer, Marketing, NYSE, EVP, Medical error, Diagnosis, Patient, Centers for Disease Control and Prevention, Obstetrics and gynaecology, MVP, Risk, Treatment, Candidiasis, BV, Stonebraker, Pharmaceutical industry, Vaccine, Vaginitis

SUNNYVALE, Calif., Nov. 15, 2022 /PRNewswire/ -- Cepheid announced today that it has launched Xpert Xpress MVP, a multiplexed PCR test which detects DNA from organisms associated with three distinct conditions – bacterial vaginosis (BV), vulvovaginal candidiasis, and trichomoniasis – from a single sample, aiding in more accurate diagnosis and antibiotic treatment regimens.

Key Points: 
  • BV is the most common cause of the vaginitis/vaginosis syndrome, but vaginitis can also be caused by Trichomonas and yeasts such asCandida.
  • Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.
  • (2021) Performance of a Vaginal Panel Assay Compared With the Clinical Diagnosis of Vaginitis.
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024683/
    6 Performance of a Vaginal Panel Assay Compared With the Clinical Diagnosis (2022).

Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Retrieved on: 
Friday, October 7, 2022
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Health Technology, Clinical Trials, LinkedIn, ASM, United States Department of Health and Human Services, Cystic Fibrosis Foundation, Disease, Risk, Biomedical Advanced Research and Development Authority, Founders Fund, Development, Infection, Debridement, Human services, Conference, QIDP, Drug development, Society, Patient, Hospital, Twitter, Mortality, Inflammation, Artificial intelligence, European Society of Clinical Microbiology and Infectious Diseases, Technology, Stenotrophomonas maltophilia, Cystic fibrosis, TKA, Administration, Acinetobacter baumannii, Department, Blood, Antimicrobial resistance, Research, Bacteria, Recurrence, Skin, MDR, Fast Track, Challenge, Gram, ESCMID, Pseudomonas aeruginosa, Poster, Algorithm, Vaccine, Pharmaceutical industry, Wellcome

Peptilogics , a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.

Key Points: 
  • Peptilogics , a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.
  • Data presented demonstrate activity of PLG0206 against multi-drug resistant pathogens and suggest that this novel antimicrobial peptide could potentially address difficult to treat bacterial infections.
  • The poster, titled Activity of the novel engineered antimicrobial peptide PLG0206 against non-fermenting Gram-negative rods, highlights data investigating PLG0206 against isolates Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophili present in skin, urinary, blood, intra-abdominal and respiratory infections.
  • PLG0206 has the potential to rapidly target bacteria and persistent pathogens that produce biofilm and evade conventional antibiotics.

Bugworks Research Inc. and Cytecare Cancer Hospitals announce collaboration to accelerate the development of cutting-edge Immuno-oncology therapies

Retrieved on: 
Monday, September 19, 2022
Laboratory, Breast, Hospital, Adenosine, Infection, Entrepreneurship, Research, Radiation, AMR, Partnership, COO, The Right Way, Immunotherapy, Patient, Cancer, Physician, CEO, Solution, Head, Neck, Drug discovery, Antimicrobial resistance, Medicine, Pharmaceutical industry, Medical imaging, Yelahanka

BENGALURU, India, Sept. 19, 2022 /PRNewswire/ -- Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration.

Key Points: 
  • BENGALURU, India, Sept. 19, 2022 /PRNewswire/ -- Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration.
  • Bugworks develops best-in-class, novel therapies for cancer and infectious diseases & has set up a dedicated research center within Cytecare, which is committed to excellence in treating cancer patients.
  • Bugworks' approach, in collaboration with Cytecare Hospitals, offers new avenues to increase the percentage of patients who would benefit from these life-saving immunotherapies.
  • Cytecare launched its flagship center, Cytecare Cancer Hospitals, a 150-bed organ-site focused cancer hospital, in November 2016 at Yelahanka, Bengaluru.

Bugworks Research Inc. and Cytecare Cancer Hospitals announce collaboration to accelerate the development of cutting-edge Immuno-oncology therapies

Retrieved on: 
Monday, September 19, 2022
Laboratory, Breast, Hospital, Adenosine, Infection, Entrepreneurship, Research, Radiation, AMR, Partnership, COO, The Right Way, Immunotherapy, Patient, Cancer, Physician, CEO, Solution, Head, Neck, Drug discovery, Antimicrobial resistance, Medicine, Pharmaceutical industry, Medical imaging, Yelahanka

BENGALURU, India, Sept. 19, 2022 /PRNewswire/ -- Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration.

Key Points: 
  • BENGALURU, India, Sept. 19, 2022 /PRNewswire/ -- Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration.
  • Bugworks develops best-in-class, novel therapies for cancer and infectious diseases & has set up a dedicated research center within Cytecare, which is committed to excellence in treating cancer patients.
  • Bugworks' approach, in collaboration with Cytecare Hospitals, offers new avenues to increase the percentage of patients who would benefit from these life-saving immunotherapies.
  • Cytecare launched its flagship center, Cytecare Cancer Hospitals, a 150-bed organ-site focused cancer hospital, in November 2016 at Yelahanka, Bengaluru.

Insight Partners with Global Nonprofit Vivli on First-Ever Industry Antimicrobial Resistance Research Platform

Retrieved on: 
Tuesday, June 21, 2022
Software, General Health, Professional Services, Pharmaceutical, Data Management, Technology, Public Relations, Investor Relations, Clinical Trials, Biotechnology, Communications, Other Technology, Health, Makerere University College of Health Sciences, Doctor of Philosophy, Solution, Time, Trust law, Industry, Public health, NSIT, Forbes, Insight Enterprises, Global health, Infection, Technology, Enterprise, Coronavirus Scientific Advisory Board (Turkey), Antimicrobial resistance, Makerere University, AMR, University of Washington Department of Global Health, Research, COVID-19, Clinical trial, MD, University, Policy, Health, NASDAQ, Korea Disease Control and Prevention Agency, Groote Schuur Hospital, Twitter, Wellcome Trust, Nuffield Department of Population Health, Center, Organization, University of Cape Town, Outline of health sciences, Risk, Pharmaceutical industry, Antibiotics, Insight, Wellcome

The revolutionary, global platform allows biopharmaceutical companies to share susceptibility data on infection-causing pathogens.

Key Points: 
  • The revolutionary, global platform allows biopharmaceutical companies to share susceptibility data on infection-causing pathogens.
  • The launch of the AMR Register platform marks a critical step in combating the growing global health threat of antimicrobial resistance, in which illnesses that were once easily treatable with antibiotics are becoming more difficult to cure, said Vivli Executive Director Rebecca Li, PhD.
  • Insight has been the nonprofits long-standing technical development and platform maintenance partner, supporting Vivlis launch of its Covid-19 data sharing portal in April 2020 and its global clinical trial research platform in 2018.
  • Data sharing initiatives include the Antimicrobial Resistance Register for AMR surveillance data and the Vivli Platform for clinical trial data.